StockData

Emergent BioSolutions vs Prestige Consumer Healthcare

EBS and PBH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How EBS and PBH compare

Prestige Consumer Healthcare is the larger company, worth 7.9 times as much as Emergent BioSolutions ($2.3B against $288M).

Prestige Consumer Healthcare grew revenue faster over the last twelve months (−1.4% versus −17.7% for Emergent BioSolutions).

Prestige Consumer Healthcare keeps more of each dollar of sales as profit, with a net margin of 15.6% compared with −40.2% at Emergent BioSolutions.

Prestige Consumer Healthcare scores higher on the StockData Score (12 against 7 for Emergent BioSolutions), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricEBSPBH
Size and price
Market cap$288M$2.3B
Share price$5.61$48.22
Change, 1 year−44.5%−19.6%
Change, 5 years−87.3%−14.5%
Beta (5Y)0.780.74
Employees900890
StockData Score
Total score712 (better)
Valuation score35 (better)
Growth score01 (better)
Performance score24 (better)
Health score22
Dividend score00
Valuation
P/E–13.5×
P/S0.4× (better)2.1×
P/B0.9× (better)1.2×
EV/EBITDA–13.1×
P/FCF1.5× (better)9.7×
FCF yield65.5% (better)10.3%
Fair value$21.84$63.54
Margin of safety74.3% (better)24.1%
Growth
Revenue growth (TTM)−17.7%−1.4% (better)
Revenue growth, 5Y average−14.0%2.9% (better)
Net income growth (TTM)−443%−19.2% (better)
EPS growth (TTM)−486%−16.2% (better)
EPS growth, 5Y average−30.4%3.8% (better)
Profitability
Gross margin48.4%53.5% (better)
Operating margin−27.7%26.3% (better)
Net margin−40.2%15.6% (better)
FCF margin29.0% (better)21.3%
Return on equity−58.2%9.1% (better)
Return on invested capital−17.3%8.2% (better)
Financial health
Debt / equity1.621.05 (better)
Net debt / EBITDA–5.98
Interest coverage−4.0×–
Current ratio4.58 (better)3.23
Altman Z-score0.321.60 (better)
Piotroski F-score7 (better)4
Dividends and buybacks
Buyback yield9.5% (better)5.3%
Shareholder yield9.5% (better)5.3%
Ownership
Held by institutions87.1%113%
Held by insiders6.0%1.4%
Insider net buying, 12 months−$986K−$203K (better)
Short interest, % of float20.9%9.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.